Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility

No abstract is available for this paper.

• Publication year

  1996

• Venue

  AIDS (London)

• Publication date

  1996-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002030-199610000-00009PMID 8902066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients.

  1995cited by this paper
• Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters

  1995cited by this paper
• Resistance of Candida species to fluconazole

  1995cited by this paper
• Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata

  1995cited by this paper
• In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus

  1994cited by this paper
• Fluconazole‐resistant candidosis in an HIV cohort

  1994cited by this paper
• Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis

  1994cited by this paper
• Itraconazole cyclodextrin solution--effective treatment for HIV-related candidosis unresponsive to other azole therapy.

  1994cited by this paper
• Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

  1994cited by this paper
• Susceptibility testing of fungi: current status of the standardization process

  1993cited by this paper
• Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach.

  1993cited by this paper
• Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1

  1993cited by this paper
• Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group

  1993cited by this paper
• Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts

  1993cited by this paper
• Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers

  1993cited by this paper
• Characterization of an azole-resistant Candida glabrata isolate

  1992cited by this paper
• Emergence ofCandida krusei infections after therapy of oropharyngeal candidiasis with fluconazole

  1991cited by this paper
• Development of resistance in candida isolates from patients receiving prolonged antifungal therapy

  1991cited by this paper
• Fluconazole resistant candida in AIDS.

  1991cited by this paper
• Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV.

  1991cited by this paper
• Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

  1990cited by this paper
• Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study.

  1990cited by this paper
• High dose oral fluconazole for oropharyngeal candidosis in AIDS.

  1990cited by this paper
• Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients.

  1988cited by this paper
• Azole resistance in Candida albicans.

  1986cited by this paper
• Miconazole-resistant Candida.

  1978cited by this paper
• Simplified, accurate method for antibiotic assay of clinical specimens.

  1966cited by this paper

• Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list

  2024cites this paper
• Surveillance of upper aerodigestive candidiasis and their antifungal susceptibility study at tertiary care hospital: A prospective study

  2024cites this paper
• AIDS-Related Mycoses

  2021cites this paper
• Caracterização do potencial antifúngico de novos sais imidazólicos em Candida albicans : estudo in vitro

  2018cites this paper
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

  2016cites this paper
• Antimicrobial photodynamic therapy for treatment of biofilm-based infections.

  2015cites this paper
• Biofilm-based Healthcare-associated Infections

  2015cites this paper
• Oral Candidiasis - A Review. -

  2014cites this paper
• Candidiasis (oropharyngeal).

  2013cites this paper
• Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediat

  2013cites this paper
• ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS.

  2012cites this paper
• Clinical Experience with Itraconazole in Systemic Fungal Infections

  2012cites this paper
• Current Management of Fungal Infections

  2012cites this paper
• Photodynamic inactivation for controlling Candida albicans infections.

  2012cites this paper
• Candidiasis (oropharyngeal).

  2012cites this paper
• Oral candidiasis – A review

  2012cites this paper
• Invasive Oesophageal Candidiasis

  2012cites this paper
• Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use

  2012cites this paper
• Êëèíè÷åñêèå îñîáåííîñòè è òàêòèêà âåäåíèÿ ïàöèåíòîâ ñ êàíäèäîçíûì ïîðàæåíèåì ïîëîñòè ðòà è ãëîòêè

  2011cites this paper
• Photodynamic therapy of bacterial and fungal biofilm infections.

  2010cites this paper
• Oropharyngeal candidiasis in the era of antiretroviral therapy.

  2010cites this paper
• Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.

  2010cites this paper
• Management of oropharyngeal and esophageal candidiasis in patients with HIV infection.

  2010cites this paper
• Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.

  2010cites this paper
• CHAPTER 60 – Systemic fungal infections

  2010cites this paper
• Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

  2009cites this paper
• Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and

  2009cites this paper
• Guias de practica clinica para el manejo de la candidiasis: actualizacion del 2009, de la Infectious Diseases Society of America

  2009cites this paper
• Candidiasis (oropharyngeal).

  2009cites this paper
• A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis

  2008cites this paper
• Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.

  2008cites this paper
• Occurrence of itraconazole-tolerant micromycetes in the soil and food products

  2008cites this paper
• AIDS-related opportunistic mycoses seen in a tertiary care hospital in North India.

  2007cites this paper
• Safety and Efficacy of Posaconazole in the Long-Term Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Patients with HIV Infection

  2007cites this paper
• Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.

  2007cites this paper
• Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

  2007cites this paper
• Fungal Opportunistic Infections in HIV Disease

  2006cites this paper
• The Postantifungal Effect (PAFE) of Itraconazole, in Comparison with Those of Miconazole and Fluconazole, on Candida Species

  2006cites this paper
• Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America.

  2005cites this paper
• Management of Resistant Candida Infections

  2004cites this paper
• 84 – Gender-Specific Issues in Fungal Infections

  2004cites this paper
• Guidelines for treatment of candidiasis.

  2004influential citation
• An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis.

  2004cites this paper
• Azoles in the Management of Systemic Fungal Infections

  2004cites this paper
• Candidiasis (oropharyngeal).

  2003cites this paper
• Susceptibility testing of fungi--current status and open questions.

  2003cites this paper
• Invasive oesophageal candidiasis: current and developing treatment options.

  2003cites this paper
• Oral candidiasis

  2002cites this paper
• Management of mycoses in surgical patients -- review of the literature.

  2002cites this paper
• Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P

  2002cites this paper
• A systematic review of the management of oral candidiasis associated with HIV/AIDS.

  2002cites this paper
• Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.

  2002cites this paper
• Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons.

  2002cites this paper
• Mucosal candidiasis.

  2002cites this paper
• Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis

  2002cites this paper
• Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

  2002cites this paper
• Review articleMucosal candidiasis

  2002cites this paper
• Candida glabrata: An Important Fungal Pathogen for the 21st Century

  2001cites this paper
• Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretrovírico de gran actividad

  2001cites this paper
• Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome.

  2001cites this paper
• Oral antifungals as prophylaxis in haematological malignancy.

  2001cites this paper
• Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients.

  2001cites this paper
• [Treatment of opportunistic infections among adult and adolescent patients infected with the human immunodeficiency virus in the era of highly active anti-retroviral therapy].

  2001cites this paper
• DNA fingerprinting of serial Candida albicans isolates obtained during itraconazole prophylaxis in patients with AIDS.

  2001cites this paper
• Prophylaxis and treatment of fungal infections associated with haematological malignancies.

  2000cites this paper
• Therapeutic Options for the Management of Oropharyngeal and Esophageal Candidiasis in HIV/AIDS Patients

  2000cites this paper
• [Invasive fungal infections in patients with hematological malignancies: a clinical approach].

  2000cites this paper
• Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection

  2000cites this paper
• Management of infections caused by Candida glabrata

  2000cites this paper
• Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.

  2000cites this paper
• Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection.

  2000cites this paper
• Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

  2000cites this paper
• Oral candidal infections and antimycotics.

  2000cites this paper
• Infecciones fúngicas invasivas en pacientes con hemopatías malignas: una aproximación clínica

  2000cites this paper
• Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.

  2000cites this paper
• Fungal infections in the immunocompromised host.

  2000cites this paper
• Does Long-Term Itraconazole Prophylaxis Result in In Vitro Azole Resistance in Mucosal Candida albicans Isolates from Persons with Advanced Human Immunodeficiency Virus Infection?

  2000cites this paper
• Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans

  1999cites this paper
• Oral and Intravenous Itraconazole for Systemic Fungal Infections in Neutropenic Haematological Patients: Meeting Report

  1999cites this paper
• Options for the Management of Mucosal Candidiasis in Patients with AIDS and HIV Infection

  1999cites this paper
• Itraconazole in Cyclodextrin Solution

  1999cites this paper
• Antifungal agents. Part II. The azoles.

  1999cites this paper
• Treatment of Fluconazole-Refractory Oropharyngeal Candidiasis with Itraconazole Oral Solution in HIV-Positive Patients

  1999cites this paper
• The management of superficial candidiasis.

  1999cites this paper
• Current and Emerging Azole Antifungal Agents

  1999influential citation
• The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review.

  1999cites this paper
• Food Interaction and Steady‐State Pharmacokinetics of Itraconazole Oral Solution in Healthy Volunteers

  1998cites this paper
• A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS.

  1998cites this paper
• Refractory mucosal candidiasis in patients with human immunodeficiency virus infection.

  1998cites this paper
• Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response?

  1998cites this paper
• Enhanced Bioavailability of Itraconazole in Hydroxypropylβ-Cyclodextrin Solution versus Capsules in Healthy Volunteers

  1998cites this paper
• Safety and Efficacy of Single-Dose Fluconazole Compared with a 7-Day Regimen of Itraconazole in the Treatment of AIDS-Related Oropharyngeal Candidiasis

  1998cites this paper
• Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.

  1998cites this paper
• Preventing and treating azole-resistant oropharyngeal candidiasis in HIV-infected patients.

  1998cites this paper
• The formation of hyphae of Candida albicans induced by cyclodextrins

  1997cites this paper
• Hiv/aids – Research and Palliative Care Dovepress Optimal Management of Oropharyngeal and Esophageal Candidiasis in Patients Living with Hiv Infection

  year unknowncites this paper